Innova Captab Limited AI Stock Analysis
Want to see IN:INNOVACAP full AI Analyst Report?
Innova Captab Limited (INNOVACAP) AI Stock Analysis
Innova Captab Limited
(NSE:INNOVACAP)
The score is driven primarily by solid growth and profitability with improving leverage, but meaningfully held back by weak cash flow conversion and historically negative free cash flow. Technicals are supportive with an established uptrend and neutral momentum, while the high P/E and low dividend yield weigh on valuation.
Innova Captab Limited (INNOVACAP) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 66.31B
- Dividend Yield
- 0.17%
- Average Volume (3M)
- 36.41K
- Price to Earnings (P/E)
- 43.2
- Beta (1Y)
- 0.61
- Revenue Growth
- 34.47%
- EPS Growth
- 20.42%
- Country
- India
- Employees
- 1,600
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Innova Captab Limited Business Overview & Revenue Model
Company Description
Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution an...
How the Company Makes Money
Innova Captab Limited primarily makes money by manufacturing and selling pharmaceutical finished dosage formulations. Its revenue model generally includes: (1) Sales of finished dosage products: income earned from supplying its own or customer-specif...
Innova Captab Limited Financial Statement Overview
Summary
Strong revenue scaling and solid profitability, with manageable/improving leverage and healthy (though normalizing) ROE. The key constraint is weak cash flow conversion: free cash flow was negative for multiple years (2022–2025) and only modestly positive in 2026, raising execution risk despite strong reported earnings.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
46Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.49B | 16.04B | 12.44B | 10.77B | 9.26B | 8.00B |
| Gross Profit | 3.95B | 5.23B | 4.30B | 3.42B | 2.35B | 1.73B |
| EBITDA | 2.67B | 2.10B | 1.86B | 1.67B | 1.23B | 987.68M |
| Net Income | 1.54B | 1.41B | 1.28B | 943.45M | 679.54M | 639.53M |
Balance Sheet | ||||||
| Total Assets | 0 | 18.37B | 15.80B | 13.21B | 10.19B | 5.75B |
| Cash, Cash Equivalents and Short-Term Investments | 682.50M | 451.54M | 652.81M | 840.92M | 70.25M | 8.75M |
| Total Debt | 0 | 3.44B | 3.38B | 2.45B | 2.37B | 1.99B |
| Total Liabilities | -10.91B | 7.47B | 6.21B | 4.90B | 6.93B | 3.67B |
| Stockholders Equity | 10.91B | 10.91B | 9.59B | 8.31B | 2.77B | 2.09B |
Cash Flow | ||||||
| Free Cash Flow | -125.34M | 343.39M | -1.09B | -1.41B | -118.67M | -209.85M |
| Operating Cash Flow | 297.19M | 1.03B | 638.44M | 1.46B | 671.24M | 588.98M |
| Investing Cash Flow | -354.74M | -1.10B | -1.52B | -4.99B | -908.43M | -1.88B |
| Financing Cash Flow | -92.25M | -51.35M | 915.33M | 3.61B | 270.92M | 1.25B |
Innova Captab Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INNOVACAP, the sentiment is Positive. The current price of 1161.60 is above the 20-day moving average (MA) of 1028.61, above the 50-day MA of 1111.49, and above the 200-day MA of 901.10, indicating a neutral trend. The MACD of -14.60 indicates Negative momentum. The RSI at 55.66 is Neutral, neither overbought nor oversold. The STOCH value of 74.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INNOVACAP.
Innova Captab Limited Peers Comparison
Overall Rating
IN:BLISSGVS65Neutral- IN:INNOVACAP62Neutral
IN:GUFICBIO58Neutral
IN:MOREPENLAB55Neutral
IN:ORCHPHARMA54Neutral
IN:UNICHEMLAB51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:BLISSGVS | 65Neutral | INR 70.17B | 42.43 | ― | 0.23% | 24.87% | 46.37% |
| IN:INNOVACAP | 62Neutral | INR 62.46B | 43.21 | ― | 0.17% | 34.47% | 20.42% |
| IN:GUFICBIO | 58Neutral | INR 46.96B | 66.53 | ― | 0.02% | 16.70% | 18.73% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:MOREPENLAB | 55Neutral | INR 52.99B | 27.67 | ― | 0.21% | 30.20% | 91.17% |
| IN:ORCHPHARMA | 54Neutral | INR 52.01B | 501.64 | ― | ― | 10.83% | -89.83% |
| IN:UNICHEMLAB | 51Neutral | INR 35.66B | 11.48 | ― | ― | 6.44% | 283.10% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:INNOVACAP | Innova Captab Limited | 1161.60 | 412.17 | 55.00% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 641.15 | 479.92 | 297.65% | |
| IN:GUFICBIO | Gufic Biosciences Limited | 485.75 | 169.43 | 53.56% | |
| IN:MOREPENLAB | Morepen Laboratories Limited | 95.00 | 48.58 | 104.64% | |
| IN:ORCHPHARMA | Orchid Pharma Limited | 857.50 | 52.80 | 6.56% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 497.30 | 32.90 | 7.08% |
Innova Captab Limited Corporate Events
Innova Captab Files Scrutinizer’s Report and Voting Results for 22nd AGM
Innova Captab Limited, a listed pharmaceutical and healthcare company with operations in Panchkula and a registered office in Navi Mumbai, held its 22nd Annual General Meeting in compliance with SEBI’s Listing Regulations. The company is traded on BS...
Innova Captab Board Clears Revised Audited FY26 Results
Innova Captab Limited has notified the stock exchanges that its board has approved revised audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following a late-night board meeting on August 2...
Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion
Innova Captab Limited’s board has approved the revision of its standalone and consolidated financial statements for the financial year ended 31 March 2026, including updated audited results, balance sheets, cash flow statements, and independent audit...
Innova Captab Revises FY26 Results and Clears Baddi Capacity Expansion
Innova Captab Limited’s board has approved a revision of the company’s standalone and consolidated financial statements for the fiscal year 2025-26, including updated audited results, balance sheets, cash flow statements and auditor reports for the y...
Innova Captab Extends Trading Window Closure Ahead of Revised FY26 Results
Innova Captab Limited has announced that its trading window for dealing in the company’s securities will remain closed for all designated persons and their immediate relatives, in line with SEBI’s Prohibition of Insider Trading Regulations and the co...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026